Table 1.
the correlation of BDNF-AS expression with the clinicopathological parameters of GC patients (n=66).
| Parameters | n(%) | BDNF-AS expression | P value | |
|---|---|---|---|---|
| Low | High | |||
| Gender | ||||
| Male | 47(71.2) | 16 | 31 | 0.312 |
| Female | 19(28.8) | 9 | 10 | |
| Age | ||||
| ≥60 years | 43(65.2) | 18 | 25 | 0.362 |
| <60 years | 23(34.8) | 7 | 16 | |
| Cancer grade | ||||
| Moderate/well | 11(16.7) | 6 | 5 | 0.212 |
| poor | 55(83.3) | 19 | 36 | |
| Cancer size(cm) | ||||
| ≥5 | 21(31.8) | 6 | 15 | 0.287 |
| <5 | 45(68.2) | 19 | 26 | |
| T-Stage | ||||
| T1-2 | 12(18.2) | 7 | 5 | 0.106 |
| T3-4 | 54(81.8) | 18 | 36 | |
| Lymphatic Metastasis | ||||
| N0-1 | 31(47.0) | 17 | 14 | 0.008 |
| N2-3 | 35(53.0) | 8 | 27 | |
| Distant Metastasis | ||||
| Yes | 8(11.67) | 0 | 8 | 0.018 |
| No | 58(88.33) | 25 | 33 | |
| TNM-Stage | ||||
| Ⅰ/Ⅱ | 22(33.3) | 13 | 9 | 0.012 |
| Ⅲ/Ⅳ | 44(66.7) | 12 | 32 | |
| CEA(ng/ml) | ||||
| ≥5 | 13(19.7) | 4 | 9 | 0.555 |
| <5 | 53(80.3) | 21 | 32 | |
| CA199(u/ml) | ||||
| <37 | 53(80.3) | 22 | 31 | 0.220 |
| ≥37 | 13(19.7) | 3 | 10 | |
| Chemotherapy | ||||
| Yes | 55(83.3) | 22 | 33 | 0.427 |
| NO | 11(16.7) | 3 | 8 | |
| PM | ||||
| Yes | 20(30.3) | 3 | 17 | 0.012 |
| No | 46(69.7) | 22 | 24 | |
Remark: Tumor Staging Guidelines: AJCC Cancer Staging Manual (8th). Abbreviations: TNM: tumor-node-metastasis, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, T-Stage: Tumor invasion stage. PM: Peritoneal Metastasis. P < 0.05: statistically significant.